Hayama Manabu, Inoue Hideki, Wada Hiromichi, Mio Tadashi
Respiratory medicine, National Hospital Organization Kyoto Medical Center, Kyoto-shi, Kyoto, Japan.
BMJ Case Rep. 2014 Feb 19;2014:bcr2013201001. doi: 10.1136/bcr-2013-201001.
We report a case of life-threatening haemoptysis after administration of dabigatran in a patient with bronchiectasis. A 72-year-old woman had received dabigatran at a dose of 110 mg twice daily for chronic atrial fibrillation. She was admitted to our hospital for cerebral infarction after a few days of self-interruption of dabigatran. After the diagnosis of cerebral infarction, administration of dabigatran was restarted. Seven days later, she suffered acute-onset massive haemoptysis and required mechanical ventilation. Dabigatran treatment was discontinued, and bronchial artery embolisation (BAE) was performed twice. The bleeding continued for 11 days, but she recovered and was discharged on day 58 after admission.
我们报告了1例支气管扩张症患者服用达比加群后出现危及生命的咯血病例。一名72岁女性因慢性心房颤动接受达比加群治疗,剂量为每日2次,每次110 mg。在自行中断达比加群几天后,她因脑梗死入住我院。脑梗死诊断明确后,重新开始服用达比加群。7天后,她突发大量咯血,需要机械通气。停用达比加群治疗,并进行了2次支气管动脉栓塞术(BAE)。出血持续了11天,但她康复了,并于入院后第58天出院。